NASDAQ:PBYIPuma Biotechnology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Puma Biotechnology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.25 +0.66 (+6.23 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$10.08Now: $11.25▼$11.3350-Day Range$7.99MA: $10.75▼$13.2452-Week Range$5.50Now: $11.25▼$15.10Volume1.25 million shsAverage Volume1.63 million shsMarket Capitalization$442.85 millionP/E RatioN/ADividend YieldN/ABeta1.3 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.Read More Beat the Market (BTM) Rank™ 1.9 Analyst's Opinion Consensus RatingPuma Biotechnology has received a consensus rating of Hold. The company's average rating score is 1.80, and is based on 1 buy rating, 6 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.63, Puma Biotechnology has a potential upside of 12.2% from its current price of $11.25.Amount of Analyst CoveragePuma Biotechnology has only been the subject of 4 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesPuma Biotechnology has received 507 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPuma Biotechnology has received 494 “underperform” votes. (Add your “underperform” vote.)Community SentimentPuma Biotechnology has received 50.65% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote “Outperform” if you believe PBYI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,328.00 in company stock.Percentage Held by InsidersOnly 21.80% of the stock of Puma Biotechnology is held by insiders.Percentage Held by Institutions92.14% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Puma Biotechnology are expected to grow in the coming year, from ($0.84) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 25.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.9Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.21 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PBYI Previous Symbol CUSIPN/A CIK1401667 Webwww.pumabiotechnology.com Phone424-248-6500Debt Debt-to-Equity Ratio12.55 Current Ratio1.75 Quick Ratio1.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$272.30 million Price / Sales1.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book25.00Profitability EPS (Most Recent Fiscal Year)($1.95) Net Income$-75,600,000.00 Net Margins-36.72% Return on Equity-500.98% Return on Assets-35.35%Miscellaneous Employees272 Outstanding Shares39,364,000Market Cap$442.85 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:PBYI Rates by TradingView Receive PBYI News and Ratings via Email Sign-up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions How has Puma Biotechnology's stock been impacted by COVID-19 (Coronavirus)? Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PBYI shares have increased by 21.4% and is now trading at $11.25. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Puma Biotechnology? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Puma Biotechnology. When is Puma Biotechnology's next earnings date? Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Puma Biotechnology. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology Inc (NASDAQ:PBYI) issued its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.77) by $0.34. The biopharmaceutical company earned $51.20 million during the quarter, compared to analysts' expectations of $44.42 million. Puma Biotechnology had a negative net margin of 36.72% and a negative return on equity of 500.98%. The company's quarterly revenue was down 48.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.21 earnings per share. View Puma Biotechnology's earnings history. What price target have analysts set for PBYI? 10 analysts have issued twelve-month target prices for Puma Biotechnology's shares. Their forecasts range from $6.00 to $17.00. On average, they expect Puma Biotechnology's share price to reach $12.63 in the next year. This suggests a possible upside of 12.2% from the stock's current price. View analysts' price targets for Puma Biotechnology. Has Puma Biotechnology been receiving favorable news coverage? Media coverage about PBYI stock has trended very negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Puma Biotechnology earned a daily sentiment score of -3.1 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutPuma Biotechnology. Are investors shorting Puma Biotechnology? Puma Biotechnology saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 7,870,000 shares, a decrease of 6.8% from the April 30th total of 8,440,000 shares. Based on an average trading volume of 1,360,000 shares, the days-to-cover ratio is presently 5.8 days. Currently, 23.2% of the company's stock are short sold. View Puma Biotechnology's Current Options Chain. Who are some of Puma Biotechnology's key competitors? Some companies that are related to Puma Biotechnology include Madrigal Pharmaceuticals (MDGL), Xencor (XNCR), Y-mAbs Therapeutics (YMAB), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Heron Therapeutics (HRTX), Zogenix (ZGNX), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Opko Health (OPK), Ironwood Pharmaceuticals (IRWD), Dicerna Pharmaceuticals (DRNA), Akcea Therapeutics (AKCA), CytoDyn (CYDY) and Arcus Biosciences (RCUS). View all competitors. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Kite Pharma (KITE), Array Biopharma (ARRY), Freeport-McMoRan (FCX) and Celgene (CELG). Who are Puma Biotechnology's key executives? Puma Biotechnology's management team includes the following people: Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 49)Dr. Richard P. Bryce, Chief Medical & Scientific Officer (Age 62)Mr. Steven Lo, Chief Commercial Officer (Age 52)Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 71)Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 50) What is Puma Biotechnology's stock symbol? Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI." Who are Puma Biotechnology's major shareholders? Puma Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (8.99%), BlackRock Inc. (7.16%), Fred Alger Management LLC (5.93%), Camber Capital Management LP (4.95%), Federated Hermes Inc. (2.56%) and Acadian Asset Management LLC (2.22%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Charles R Eyler, Douglas M Hunt and Richard Paul Bryce. View institutional ownership trends for Puma Biotechnology. Which major investors are selling Puma Biotechnology stock? PBYI stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Ikarian Capital LLC, WINTON GROUP Ltd, Deutsche Bank AG, Rafferty Asset Management LLC, Parametric Portfolio Associates LLC, Two Sigma Advisers LP, and Jane Street Group LLC. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Douglas M Hunt, and Richard Paul Bryce. View insider buying and selling activity for Puma Biotechnology. Which major investors are buying Puma Biotechnology stock? PBYI stock was acquired by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Sofinnova Investments Inc., Fred Alger Management LLC, Tang Capital Management LLC, Federated Hermes Inc., UBS Group AG, Trexquant Investment LP, and Thrivent Financial for Lutherans. View insider buying and selling activity for Puma Biotechnology. How do I buy shares of Puma Biotechnology? Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Puma Biotechnology's stock price today? One share of PBYI stock can currently be purchased for approximately $11.25. How big of a company is Puma Biotechnology? Puma Biotechnology has a market capitalization of $442.85 million and generates $272.30 million in revenue each year. The biopharmaceutical company earns $-75,600,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Puma Biotechnology employs 272 workers across the globe. What is Puma Biotechnology's official website? The official website for Puma Biotechnology is www.pumabiotechnology.com. How can I contact Puma Biotechnology? Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
